Novartis, Celgene meds take the biggest shares of cancer drug spending

Cancer drug spending is up. Cancer drug prices are way up. And as a new Express Scripts ($ESRX) report shows, spending on each cancer patient is mounting; it's among the reasons why a growing number of individual patients account for $100,000-plus in annual drug spending. And a few big drugs made big contributions to that rise.

As the American Society of Clinical Oncology meeting approaches, the pharmacy benefits manager released some numbers on cancer drug spending. The top line? Spending on cancer meds grew by more than one-fifth last year, with a 9% increase in use and almost 12% increase in prices.

Prime suspects for that increase? The leukemia treatment Gleevec, from Novartis ($NVS), which boasts the biggest share of the market at 12.5%. Fellow blood cancer treatment Revlimid--the multiple myeloma therapy from Celgene ($CELG)--came in close behind with 10.8% of pharmacy benefit spending.

In third place by market share is Lupron Depot, the AbbVie ($ABBV) med used to treat several conditions, including prostate cancer. And rounding out the top 5 were two newly generic chemotherapies, capecitabine, also sold by Roche ($RHHBY) under the brand name Xeloda; and temozolomide, the Merck & Co. ($MRK) pill Temodar that's used to treat brain tumors.

And the growth shows no sign of slowing, the PBM said in a blog post, partly because of new meds coming to market--including Pfizer's ($PFE) blockbuster-to-be breast cancer med Ibrance (palbociclib), Novartis' myeloma med Farydak (panobinostat) and Eisai's thyroid cancer treatment Lenvima (lenvatinib). Not to mention the PD-1/PD-L1 immunotherapies that are swiftly racking up data (and approvals) in multiple cancers, including Merck's Keytruda and Bristol-Myers Squibb's ($BMY) Opdivo.

"Express Scripts expects cancer medications will maintain their lead position as a major contributor to drug spending in the pharmacy benefit, due to the availability of new medications and increased survival requiring long-term use of expensive and complex treatment," the PBM notes.

That's why Express Scripts is so keen on negotiating discounts with drugmakers, including pay-for-performance deals that would peg prices to results. It's also why Express Scripts is impatiently waiting for--and lobbying on the behalf of--biosimilar meds. The PBM says 11 biosimilars closest to FDA approval could save the healthcare system $250 billion over the next decade. That would include Roche's Avastin (bevacizumab) and Herceptin (trastuzumab), two of the top-selling cancer meds on the planet.

- read the Express Scripts blog post

Special Report: Top 10 best-selling cancer treatments of 2013 - Avastin - Herceptin - Gleevec - Revlimid - Lupron

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…